Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of Gemtuzumab Ozogamicin (Mylotarg) Plus Conventional Chemotherapy in De Novo AML in Patients <30 Years
2016-001533-28Phase 3
- Sponsor
- Children's Oncology Group
- Start
- May 2016
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML) (2 arms), sponsored by Children's Oncology Group. Primary endpoints: Overall survival at 3 years and Event-free survival at 3 years.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2016-001533-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001533-28.